The efficacy of platelet rich plasma on women with poor ovarian response: a systematic review and meta-analysis

References

• Racca A, Drakopoulos P, Neves AR, Polyzos NP. Current therapeutic options for controlled ovarian stimulation in assisted reproductive technology. Drugs. 2020;80(10):973–10. doi:10.1007/s40265-020-01324-w.
   PubMed Web of Science ®Google Scholar
• Quaas AM, Legro RS. Pharmacology of medications used for ovarian stimulation. Best Pract Res Clin Endocrinol Metab. 2019;33(1):21–33. doi:10.1016/j.beem.2018.10.002.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang C, Shu J, Guo J, Chang H-M, Leung PCK, Sheng J-Z, Huang H. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum Reprod Update. 2020;26(2):247–263. doi:10.1093/humupd/dmz046.
   PubMed Web of Science ®Google Scholar
• Giannelou P, Simopoulou M, Grigoriadis S, Makrakis E, Kontogeorgi A, Pantou A, Galatis D, Kalampokas T, Bakas P, Bolaris S, et al. The conundrum of poor ovarian response: from diagnosis to treatment. Diagnostics (Basel, Switzerland). 2020;10(9):687. doi:10.3390/diagnostics10090687.
   PubMedGoogle Scholar
• Devine K, Mumford SL, Wu M, DeCherney AH, Hill MJ, Propst A. Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the society for assisted reproductive technology clinic outcomes reporting System. Fertil Steril. 2015;104(3):612–619.e613. doi:10.1016/j.fertnstert.2015.05.017.
   PubMed Web of Science ®Google Scholar
• Pirtea P, Ayoubi JM. Diminished ovarian reserve and poor response to stimulation are not reliable markers for oocyte quality in young patients. Fertil Steril. 2020;114(1):67–8. doi:10.1016/j.fertnstert.2020.03.040.
   PubMed Web of Science ®Google Scholar
• Glujovsky D, Quinteiro Retamar AM, Alvarez Sedo CR, Ciapponi A, Cornelisse S, Blake D. Cleavage-stage versus blastocyst-stage embryo transfer in assisted reproductive technology. Cochrane Database Syst Rev. 2022;2022(6):Cd002118. doi:10.1002/14651858.CD002118.pub6.
   Google Scholar
• Pantou A, Giannelou P, Grigoriadis S, Maziotis E, Tzonis P, Koutsouni A, Pappa C, Philippou A, Koutsilieris M, Pantos K, et al. Evaluating different strategies for poor ovarian response management: a retrospective cohort study and literature review. Ann NY Acad Sci. 2021;1500(1):93–111. doi:10.1111/nyas.14614.
   PubMed Web of Science ®Google Scholar
• Labarta E. DuoStim: a new strategy proposed for women with poor ovarian response. Fertil Steril. 2020;113(1):76–7. doi:10.1016/j.fertnstert.2019.10.024.
   PubMed Web of Science ®Google Scholar
• Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci. 2020;21(20):7794. doi:10.3390/ijms21207794.
   PubMed Web of Science ®Google Scholar
• Streit-Ciećkiewicz D, Kołodyńska A, Futyma-Gąbka K, Grzybowska ME, Gołacki J, Futyma K. Platelet rich plasma in gynecology—discovering undiscovered—review. Int J Environ Res Public Health. 2022;19(9):5284. doi:10.3390/ijerph19095284.
   PubMed Web of Science ®Google Scholar
• Sills ES, Wood SH. Autologous activated platelet-rich plasma injection into adult human ovary tissue: molecular mechanism, analysis, and discussion of reproductive response. Biosci Rep. 2019;39(6). doi:10.1042/BSR20190805.
   PubMedGoogle Scholar
• Marchante M, Buigues A, Ramirez-Martin N, Martinez J, Pellicer N, Pellicer A, Herraiz S. Single intraovarian dose of stem cell– and platelet-secreted factors mitigates age-related ovarian infertility in a murine model. Am J Obstet Gynecol. 2023;228(5):561.e561–561.e517. doi:10.1016/j.ajog.2023.01.018.
   Web of Science ®Google Scholar
• Seckin S, Ramadan H, Mouanness M, Kohansieh M, Merhi Z. Ovarian response to intraovarian platelet-rich plasma (PRP) administration: hypotheses and potential mechanisms of action. J Assist Reprod Genet. 2022;39(1):37–61. doi:10.1007/s10815-021-02385-w.
   PubMed Web of Science ®Google Scholar
• Herlihy NS, Seli E. The use of intraovarian injection of autologous platelet rich plasma (PRP) in patients with poor ovarian response and premature ovarian insufficiency. Curr Opin Obstet Gynecol. 2022;34(3):133–7. doi:10.1097/GCO.0000000000000784.
   PubMed Web of Science ®Google Scholar
• Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657–1665. doi:10.1001/jama.2015.3656.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clinical Research Ed). 2016;355:i4919. doi:10.1136/bmj.i4919.
   PubMed Web of Science ®Google Scholar
• Navali N, Sadeghi L, Farzadi L, Ghasemzadeh A, Hamdi K, Hakimi P, Niknafs B. Intraovarian injection of autologous platelet-rich plasma improves therapeutic approaches in the patients with poor ovarian response: a before-after study. Int J Fertil Steril. 2022;16(2):90–94. doi:10.22074/IJFS.2021.533576.1154.
   PubMed Web of Science ®Google Scholar
• Keikha F, Shahsavari S, Salari Y, Roozbeh N, Haghollahi F, Tarazjani MD, Razavi M, Shariat M, Bagheri M. One side ovarian rejuvenation: a quasi-experimental study of the effect of the autologous platelet rich plasma in poor ovarian responders in IVF. Ethiop J Health Sci. 2022;32(6):1133–1140. doi:10.4314/ejhs.v32i6.10.
   PubMed Web of Science ®Google Scholar
• Pacu I, Zygouropoulos N, Dimitriu M, Rosu G, Ionescu CA. Use of platelet-rich plasma in the treatment of infertility in poor responders in assisted human reproduction procedures. Exp Ther Med. 2021;22(6):1412. doi:10.3892/etm.2021.10848.
   PubMed Web of Science ®Google Scholar
• Farimani M, Nazari A, Mohammadi S, Anvari Aliabad R. Evaluation of intra-ovarian platelet-rich plasma administration on oocytes-dependent variables in patients with poor ovarian response: a retrospective study according to the POSEIDON criteria. Reprod Biol Endocrinol. 2021;19(1):137. doi:10.1186/s12958-021-00826-w.
   PubMed Web of Science ®Google Scholar
• Cakiroglu Y, Yuceturk A, Karaosmanoglu O, Kopuk SY, Korun ZEU, Herlihy N, Scott RT, Tiras B, Seli E. Ovarian reserve parameters and IVF outcomes in 510 women with poor ovarian response (POR) treated with intraovarian injection of autologous platelet rich plasma (PRP). Aging. 2022;14(6):2513–2523. doi:10.18632/aging.203972.
   PubMedGoogle Scholar
• Tülek F, Kahraman A. The effects of intra-ovarian autologous platelet rich plasma injection on IVF outcomes of poor responder women and women with premature ovarian insufficiency. J Turkish German Gynecol Assoc. 2022;23(1):14–21. doi:10.4274/jtgga.galenos.2021.2021.0134.
   PubMed Web of Science ®Google Scholar
• Aflatoonian A, Lotfi M, Saeed L, Tabibnejad N. Effects of intraovarian injection of autologous platelet-rich plasma on ovarian rejuvenation in poor responders and women with primary ovarian insufficiency. Reprod Sci (Thousand Oaks, Calif). 2021;28(7):2050–2059. doi:10.1007/s43032-021-00483-9.
   PubMed Web of Science ®Google Scholar
• Sfakianoudis K, Simopoulou M, Grigoriadis S, Pantou A, Tsioulou P, Maziotis E, Rapani A, Giannelou P, Nitsos N, Kokkali G, et al. Reactivating ovarian function through autologous platelet-rich plasma intraovarian infusion: Pilot data on premature ovarian insufficiency, perimenopausal, menopausal, and poor responder women. J Clin Med. 2020;9(6):1809. doi:10.3390/jcm9061809.
   PubMed Web of Science ®Google Scholar
• Parvanov D, Ganeva R, Vidolova N, Nikolova K, Vasileva M, Totev T, Stamenov G. Autologous ovarian platelet rich plasma treatment improves oocyte and embryo quality: a before-after prospective study. Biotechnol Biotechnol Equip. 2022;36(1):425–32. doi:10.1080/13102818.2022.2090280.
   Web of Science ®Google Scholar
• Stojkovska S, Dimitrov G, Stamenkovska N, Hadzi-Lega M, Petanovski Z. Live birth rates in poor responders’ group after previous treatment with autologous platelet-rich plasma and low dose ovarian stimulation compared with poor responders used only low dose ovarian stimulation before in vitro fertilization. Open Access Maced J Med Sci. 2019;7(19):3184–8. doi:10.3889/oamjms.2019.825.
   PubMedGoogle Scholar
• Farimani M, Heshmati S, Poorolajal J, Bahmanzadeh M. A report on three live births in women with poor ovarian response following intra-ovarian injection of platelet-rich plasma (PRP). Mol Biol Rep. 2019;46(2):1611–16. doi:10.1007/s11033-019-04609-w.
   PubMed Web of Science ®Google Scholar
• Garner AL, Frelinger AL 3rd, Gerrits AJ, Gremmel T, Forde EE, Carmichael SL, Michelson AD, Neculaes VB. Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting. Med Hypotheses. 2019 Apr;125:100–105. doi:10.1016/j.mehy.2019.02.036.
   PubMed Web of Science ®Google Scholar
• Irmak G, Demirtaş TT, Gümüşderelioğlu M. Sustained release of growth factors from photoactivated platelet rich plasma (PRP). Eur J Pharm Biopharm. 2020;148:67–76. doi:10.1016/j.ejpb.2019.11.011.
   PubMed Web of Science ®Google Scholar
• Martineau I, Lacoste E, Fau - Gagnon G, Gagnon G. Effects of calcium and thrombin on growth factor release from platelet concentrates: kinetics and regulation of endothelial cell proliferation. Biomaterials. 2004 Aug;25(18):4489–502. doi:10.1016/j.biomaterials.2003.11.013.
   PubMed Web of Science ®Google Scholar
• Sills ES, Wood SH, Walsh APH. Intraovarian condensed platelet cytokines for infertility and menopause-mirage or miracle? Biochimie. 2023 Jan;204:41–47. doi:10.1016/j.biochi.2022.08.020.
   PubMed Web of Science ®Google Scholar
• Fadadu P-O, Mazzola AJ, Hunter CW, Davis TT. Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization. Reg Anesth Pain Med. 2019 Apr;16(1532–8651). doi:10.1136/rapm-2018-100356.
   Google Scholar
• Sills ES, Rickers N, Wood S. Regenerative effect of intraovarian injection of activated autologous platelet rich plasma: serum anti-mullerian hormone levels measured among poor prognosis IVF patients. Int J Regenr Med. 2020;2613–5914:1–5. doi:10.31487/j.RGM.2020.01.02.
   Google Scholar
• Atkinson L, Martin F, Sturmey RG. Intraovarian injection of platelet-rich plasma in assisted reproduction: too much too soon? Hum Reprod (Oxford, England). 2021;36(7):1737–50. doi:10.1093/humrep/deab106.
   PubMed Web of Science ®Google Scholar
• Hsu CC, Hsu I, Hsu L, Chiu YJ, Dorjee S. Resumed ovarian function and pregnancy in early menopausal women by whole dimension subcortical ovarian administration of platelet-rich plasma and gonadotropins. Menopause (New York, NY). 2021;28(6):660–6. doi:10.1097/GME.0000000000001746.
   PubMed Web of Science ®Google Scholar
• Sharara FI, Lelea LL, Rahman S, Klebanoff JS, Moawad GN. A narrative review of platelet-rich plasma (PRP) in reproductive medicine. J Assist Reprod Genet. 2021;38(5):1003–12. doi:10.1007/s10815-021-02146-9.
   PubMed Web of Science ®Google Scholar
• Callejo J, Salvador C, González-Nuñez S, Almeida L, Rodriguez L, Marqués L, Valls A, Lailla JM. Live birth in a woman without ovaries after autograft of frozen-thawed ovarian tissue combined with growth factors. J Ovarian Res. 2013;6(1):33. doi:10.1186/1757-2215-6-33.
   PubMedGoogle Scholar
• Ahmadian S, Sheshpari S, Pazhang M, Bedate AM, Beheshti R, Abbasi MM, Nouri M, Rahbarghazi R, Mahdipour M. Intra-ovarian injection of platelet-rich plasma into ovarian tissue promoted rejuvenation in the rat model of premature ovarian insufficiency and restored ovulation rate via angiogenesis modulation. Reprod Biol Endocrinol. 2020;18(1):78. doi:10.1186/s12958-020-00638-4.
   PubMed Web of Science ®Google Scholar
• Abu-Musa A, Haahr T, Humaidan P. Novel physiology and definition of poor ovarian response; clinical recommendations. Int J Mol Sci. 2020;21(6):2110. doi:10.3390/ijms21062110.
   PubMed Web of Science ®Google Scholar